.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
US Department of Justice
Queensland Health
Fish and Richardson
Mallinckrodt
Merck
Healthtrust
QuintilesIMS
Daiichi Sankyo
Colorcon

Generated: November 20, 2017

DrugPatentWatch Database Preview

PARICALCITOL - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for paricalcitol and what is the scope of paricalcitol patent protection?

Paricalcitol
is the generic ingredient in two branded drugs marketed by Abbvie, Sandoz Inc, Eci Pharms Llc, Dr Reddys Labs Ltd, Hikma Pharms, Rising Pharms Inc, Amneal Pharms, Teva Pharms Usa, Bionpharma Inc, Marksans Pharma, Hospira Inc, Aurobindo Pharma Ltd, Accord Hlthcare, and Amneal Pharms Co, and is included in sixteen NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Paricalcitol has seventeen patent family members in ten countries and one supplementary protection certificate in one country.

There are ten drug master file entries for paricalcitol. Eighteen suppliers are listed for this compound. There is one tentative approval for this compound.

Pharmacology for PARICALCITOL

Ingredient-typeCholecalciferol
Drug ClassVitamin D3 Analog

Tentative approvals for PARICALCITOL

Applicant Application No. Strength Dosage Form
u► Subscribe2MCG/MLINJECTABLE; INJECTION
u► Subscribe10MCG/MLINJECTABLE; INJECTION
u► Subscribe5MCG/MLINJECTABLE; INJECTION
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma Pharms
PARICALCITOL
paricalcitol
SOLUTION;INTRAVENOUS205917-002Nov 18, 2014APRXNoNo► Subscribe► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-002Feb 1, 2000APRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-002May 26, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Amneal Pharms Co
PARICALCITOL
paricalcitol
SOLUTION;INTRAVENOUS206699-002Mar 9, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Hikma Pharms
PARICALCITOL
paricalcitol
SOLUTION;INTRAVENOUS205917-001Nov 18, 2014APRXNoNo► Subscribe► Subscribe► Subscribe
Eci Pharms Llc
PARICALCITOL
paricalcitol
CAPSULE;ORAL206710-003Feb 24, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Amneal Pharms
PARICALCITOL
paricalcitol
CAPSULE;ORAL204327-001Jan 13, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
PARICALCITOL
paricalcitol
CAPSULE;ORAL090829-002Sep 27, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
PARICALCITOL
paricalcitol
CAPSULE;ORAL090829-003Sep 27, 2013ABRXNoYes► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
PARICALCITOL
paricalcitol
CAPSULE;ORAL207672-003Jan 14, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: paricalcitol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-001Apr 17, 1998► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-002May 26, 2005► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-001May 26, 2005► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-003May 26, 2005► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-003May 26, 2005► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-003May 26, 2005► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-001Apr 17, 1998► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-002Feb 1, 2000► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-001Apr 17, 1998► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-002Feb 1, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: paricalcitol

Country Document Number Estimated Expiration
Japan2014129360► Subscribe
Japan2016053046► Subscribe
Austria275974► Subscribe
Canada2326198► Subscribe
Japan4664499► Subscribe
Australia758989► Subscribe
Denmark1073467► Subscribe
Australia3359899► Subscribe
Japan2011037860► Subscribe
Portugal1073467► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PARICALCITOL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/003United Kingdom► SubscribePRODUCT NAME: PARICALCITOL; REGISTERED: ES SPAIN 64.974 20020809; UK PL 00037/0403 20030721
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
Medtronic
Julphar
Citi
UBS
Covington
Fish and Richardson
US Department of Justice
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot